Ablagerung von gadoliniumhaltigen Kontrastmitteln im Gehirn nach mehrfacher Anwendung: Konsequenzen für den Einsatz der MRT bei Diagnosestellung und Verlaufsbeurteilung in der Multiplen Sklerose

Akt Neurol 2016; 43: 237 – 241

• Literatur

• 1 Lukas C, Gold R, Fiehler J et al. Ablagerung von gadoliniumhaltigen Kontrastmitteln im Gehirn nach mehrfacher Anwendung: Konsequenzen für den Einsatz der MRT bei Diagnosestellung und Verlaufsbeurteilung der Multiplen Sklerose?. Akt Neurol 2016; 43: 237-241
• 2 Gibby WA, Gibby KA, Gibby WA. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 2004; 39: 138-142
• 3 White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006; 41: 272-278
• 4 Darrah TH, Prutsman-Pfeifer JJ, Poreda RJ et al. Incorporations of excess gadolinium into human bone from medical contrast agents. Metallomics 2009; 1: 479-488
• 5 Rogosnitzky M, Branch S. Gadolinium-based contrast agent toxicity: a review of know and proposed mechanis. Biometals 2016; (published online 06 April 2016)
• 6 Murata N, Gonzalez-Cuyar LF, Murata K et al. Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: Preliminary results from 9 patients with normal renal function. Invest Radiol 2016; 51: 447-453
• 7 Ramalho J, Semelka RC, AIObaidy M et al. Signal intensity change on unenhanced T1-weighted images in dentate nucleus following gadobenate dimeglumine in patients with and without previous multiple administrations of gadodiamide. Eur Radiol 2016; Feb 24 [Epub ahead of print]
• 8 Blystad I, Hakansson I, Tisell a et al. Quantitative MRI for Analysis of active multiple sclerosis lesions without gadolinium-based contrast agent. Am J Neuroradiol 2016; 37: 94-100
• 9 Wattjes MP, Rovira A, Miller D et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis – establishing disease prognosis and monitoring patients. Nature Reviews Neurology 2015; 11: 597-606
• 10 Ohl K, Tenbrock K, Kipp M. Oxidative stress in multiple sclerosis: Central and peripheral mode of action. Experimental Neurology 2016; 277: 58-67
• 11 Semelka RC, Ramalho M, AlObaidy M et al. Gadolinium in humans: A family of disorders. American Journal of Roentgenology 2016; 207: 229-233
• 12 Traboulsee A, Simon JH, Stone L et al. Revised recommendations of the consortium of MS centers task force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis. Am J Neuroradiol 2016; 37: 394-401